Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 in adults with heterozygous familial hypercholesterolemia
NCT05952869Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Countries
- 17
01
Overview
A Phase 3 trial of enlicitide in heterozygous familial hypercholesterolemia (HeFH), sponsored by Merck & Co.. Started Aug 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT05952869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952869.